MLYS — Mineralys Therapeutics, Inc. stock price, charts and financials
QT64Mineralys Therapeutics, Inc.Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
26.50
+0.72+2.79%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 35.39% | Shs Outstand | 88.16M | Perf Week | -1.67% |
| Market Cap | 2.34B | Forward P/E | - | EPS next Y | -2.10 | Insider Trans | -0.19% | Shs Float | 61.91M | Perf Month | -9.00% |
| Enterprise Value | 1.68B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 15.43% | Perf Quarter | -10.62% |
| Income | -155.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 6.20 | Perf Half Y | -14.16% |
| Sales | 0.00 | P/B | 3.61 | EPS next Y | 9.25% | ROA | -23.25% | Short Interest | 9.55M | Perf YTD | -26.98% |
| Book/sh | 7.34 | P/C | 3.56 | EPS next 5Y | - | ROE | -27.92% | 52W High | 47.65 -44.39% | Perf Year | 93.86% |
| Cash/sh | 7.45 | P/FCF | - | EPS past 3/5Y | - | ROIC | -26.87% | 52W Low | 12.59 110.48% | Perf 3Y | 82.38% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 4.28% 4.37% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 43.99% | Oper. Margin | 0.00% | ATR (14) | 1.28 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 44.33 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 47.36 | Recom | 2.13 |
| Dividend Gr. 3/5Y | - | Current Ratio | 44.33 | EPS Q/Q | 40.51% | SMA20 | -2.49% | Beta | 0.74 | Target Price | 43.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -1.39% | Rel Volume | 0.47 | Prev Close | 25.78 |
| Employees | 76 | LT Debt/Eq | - | Earnings | Aug 11 | SMA200 | -15.50% | Avg Volume | 1.43M | Price | 26.50 |
| IPO Date | Feb 10, 2023 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.46% - | Net Debt/EBITDA | 0.74 | Volume | 663,821 | Change | 2.79% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Mar-13-26 | Reiterated | Jefferies | Hold | $30 |
| Mar-10-26 | Reiterated | H.C. Wainwright | Buy | $52 → $56 |
| Dec-19-25 | Reiterated | Stifel Nicolaus | $45 → $52 | |
| Oct-30-25 | Reiterated | HC Wainwright & Co. | Buy | $42 → $52 |
| May-14-25 | Reiterated | Guggenheim | Buy | $52 → $48 |
| Apr-02-25 | Reiterated | HC Wainwright & Co. | Buy | $42 |
| Apr-02-24 | Reiterated | Goldman Sachs | $30 |
Latest News
Jul-27-26
Jul-27-2604:01PM
Jul-03-26
Jul-03-2601:41PM
Jun-17-26
01:35PM
Jun-15-26
Jun-15-2603:01AM
Jun-11-26
Company
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 39 | 24 | 14 | 5 | 2 | 1 | |
| Research and Development | 132 | 169 | 70 | 26 | 16 | 2 | |
| Other Operating Expense | 0 | -1 | 1 | 0 | 1 | 0 | |
| Operating Income | -171 | -192 | -85 | -31 | -19 | -3 | |
| Interest Expense | 0 | 0 | 0 | 2 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 16 | 15 | 13 | 3 | -1 | 0 | |
| Net Income Before Taxes | -155 | -178 | -72 | -30 | -19 | -3 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -155 | -178 | -72 | -30 | -19 | -3 | |
| Net Income From Continuing Operations | -155 | -178 | -72 | -30 | -19 | -3 | |
| Net Income | -155 | -178 | -72 | -30 | -19 | -3 | |
| EPS (Recurring) | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 | |
| EPS (Basic, Before Extraordinaries) | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 | |
| EPS (Diluted) | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 | |
| EBITDA | -155 | -178 | -72 | -28 | -19 | -3 | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | |
| Shares Outstanding | 68 | 49 | 36 | 5 | 5 | 5 | |
| Market Capitalization | 2,468 | 603 | 310 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Warren Eric | Chief Commercial Officer | Jul 21 '26 | Sale | 26.87 | 7,438 | 199,885 | 38,400 | Jul 23 |
| Warren Eric | Chief Commercial Officer | Jul 21 '26 | Option Exercise | 13.24 | 7,438 | 98,479 | 45,838 | Jul 23 |
| Rodman David Malcom | Chief Medical Officer | Jul 17 '26 | Sale | 26.53 | 416 | 11,036 | 51,384 | Jul 20 |
| Rodman David Malcom | Chief Medical Officer | Jul 17 '26 | Option Exercise | 15.44 | 416 | 6,423 | 51,800 | Jul 20 |
| Rodman David Malcom | Chief Medical Officer | Jul 15 '26 | Sale | 26.61 | 6,349 | 168,955 | 51,384 | Jul 15 |
| Rodman David Malcom | Chief Medical Officer | Jul 13 '26 | Option Exercise | 7.28 | 14,058 | 102,365 | 71,791 | Jul 15 |
| Rodman David Malcom | Chief Medical Officer | Jul 13 '26 | Sale | 27.58 | 14,058 | 387,717 | 57,733 | Jul 15 |
| Congleton Jon | Chief Executive Officer | Jul 13 '26 | Sale | 27.24 | 10,700 | 291,441 | 603,621 | Jul 15 |
| Rodman David Malcom | Chief Medical Officer | Jul 09 '26 | Sale | 30.30 | 2,171 | 65,781 | 57,733 | Jul 10 |
| Rodman David Malcom | Chief Medical Officer | Jul 09 '26 | Option Exercise | 16.00 | 2,171 | 34,736 | 59,904 | Jul 10 |
| Congleton Jon | Chief Executive Officer | Jun 30 '26 | Sale | 26.14 | 75,000 | 1,960,602 | 614,321 | Jun 30 |
| Warren Eric | Chief Commercial Officer | Jun 26 '26 | Option Exercise | 13.24 | 104,124 | 1,378,602 | 142,524 | Jun 30 |
| Warren Eric | Chief Commercial Officer | Jun 26 '26 | Sale | 25.90 | 104,124 | 2,696,322 | 38,400 | Jun 30 |
| Rodman David Malcom | Chief Medical Officer | Jun 17 '26 | Option Exercise | 14.36 | 4,584 | 65,818 | 61,679 | Jun 17 |
| Rodman David Malcom | Chief Medical Officer | Jun 17 '26 | Sale | 25.00 | 4,584 | 114,600 | 57,095 | Jun 17 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.